https://www.selleckchem.com/products/cmc-na.html
46), respectively, for a DD of 12 months and 1 to ≤12 months compared to 1month. In patients receiving anti-TNFα agents, the multivariable-adjusted odds ratios for high medical cost were 2.63 (1.34-5.16) and 1.35 (0.79-2.28) for a DD of 12 months and 1 to ≤12 months, respectively, compared to 1month. In patients without anti-TNFα, multivariable logistic regression analyses were not presented because of a small number of patients categorized into the high medical cost group. A delayed diagnosis of CD may incur high medical
Like
Comment
Share
